Christopher A. Viehbacher
President and Chief Executive Officer
Executive
3 yr
5 reports
Biogen Inc. ·BIIB
Enterprise model with R&D and operations reporting directly to CEO
Health Care · Fortune #424 · Hybrid structure · 8K employees · Cambridge, Massachusetts
5
CEO span
↓ tighter than peers (avg 10)
5
Avg span
wide
2
Max depth
2 levels
6 yr
Avg tenure
20%
Internal hires
↓ below industry avg
Consolidated financials FY2025 · period end 2025-12-31 · 10-K
Revenue
$9.9B
Operating income
$2.8B
Net income
$1.3B
Total assets
$29.4B
Shares out
147M
Sourced from Biogen Inc. DEF 14A · filed 2026-04-28 ↗ View on SEC
Interactive org chart
Biogen Inc. organizational chart
Explore the executive structure, reporting layers, and scenario-ready operating model from public filings.
Open editable chart
Take this model into your AI workspace Use AI to reason through the model, then bring the scenario back into Creately Atlas.
Choose a prompt, then open an AI app and paste.
Download the CSV data instead
Biogen operates a flat enterprise structure where R&D, development, and operations all report directly to the CEO. This page maps the executive team, highlights recent leadership changes, and analyzes how Biogen’s structure compares with major pharmaceutical peers.
What to model
Use the chart to test org decisions, not just view reporting lines
Start with the public baseline, then use the scenario views and source-backed changes to ask what happens when leadership, span, or team ownership shifts.
Latest signal Robin C. Kramer moved into Chief Financial Officer
Promoted to EVP and CFO effective March 1, 2025.
Source · See change logScenario views in the chart
- Appoint New Chief Legal Officer Following Susan Alexander’s departure, Biogen could appoint a new CLO to maintain regulatory and governance continuity.
- Add Chief Operating Officer Adding a COO could reduce the CEO’s operational span and centralize manufacturing and supply-chain execution.
Atlas work this supports
- Connect Workday or UKG Get these analytics for YOUR org — tenure, span of control, headcount, automatically from your HRIS.
- Connect Salesforce Map your target accounts like this. Import contacts, visualize decision chains, plan multi-threading.
- Plan a Reorg Use this as a starting point. Model scenarios, compare structures, present options to your board.
The people
Who's running this
6 executives identified as Named Executive Officers in the most recent SEC proxy. Bar length scales with tenure.
internal
Robin C. Kramer
Executive Vice President and Chief Financial Officer
Finance
1 yr
0 reports
Susan H. Alexander
Executive Vice President, Chief Legal Officer
Legal
20 yr
0 reports
Priya A. Singhal
Head of Development
R&D
3 yr
0 reports
Nicole C. Murphy
Head of Pharmaceutical Operations and Technology
Operations
3 yr
0 reports
Rachid Izzar
Head of Research
R&D
6 yr
0 reports
The businesses
How Biogen Inc. divides the work
3 divisions report into the group CEO. Tile size scales with estimated headcount.
Research
2K employees
Head of Research (Rachid Izzar)
Responsible for discovery and early-stage research across Biogen’s neuroscience and immunology pipeline.
Development
2K employees
Head of Development (Priya A. Singhal)
Leads clinical development, regulatory strategy, and late-stage pipeline execution.
Pharmaceutical Operations and Technology
2K employees
Head of Pharmaceutical Operations and Technology (Nicole C. Murphy)
Oversees manufacturing, supply chain, quality, and core technology platforms.
The thesis
Why this org is unusual
Biogen’s most distinctive structural feature is its enterprise-style model in which core scientific, operational, and corporate functions all report directly to the CEO rather than being grouped under a COO.
This creates a wide CEO span with direct accountability for R&D, development, and manufacturing at the top. The structure reflects Biogen’s strategic emphasis on scientific execution and pipeline delivery following years of restructuring.
The organization is functionally strong at level two, with clear separation between research, development, operations, finance, and legal. Notably, pharmaceutical operations and technology remain combined under a single executive, reinforcing tight integration between manufacturing and digital capabilities. Legal has historically been long-tenured, though a transition is underway.
Overall, the chart shows a relatively shallow hierarchy for a global pharmaceutical company, consistent with Biogen’s reduced scale post-divestitures and its focus on a smaller number of high-value therapeutic areas.
- No COO role
- R&D and operations report directly to CEO
- Relatively flat executive hierarchy
The comparison
How Biogen Inc. stacks up
Compared with large-cap pharma peers such as AbbVie, Merck, and Bristol Myers Squibb, Biogen operates with a flatter executive structure and fewer divisional presidents. Many peers insert an additional layer of group or franchise heads between the CEO and R&D or commercial leaders. Biogen’s model more closely …
C-suite size
Reporting depth
Avg C-suite tenure
Has COO / Has CAIO
Biogen Inc. — no COO — no CAIO
Regeneron — no COO — no CAIO
Current signals
What changed recently
The most significant recent change is the announced departure of long-tenured Chief Legal Officer Susan Alexander in mid-2026.
- promoted
- Date not confirmed departed
Leadership Timeline
Year-over-year executive structure based on SEC proxy and annual filings.
FY2025
DEF 14A filed 2026-04-28
- CEO
- Christopher A. Viehbacher
- CEO span
- 5
- C-suite
- 6
- Avg tenure
- 6 yr
Leadership reflects post-restructuring focus on a streamlined executive team.
Named executive officers (5)
- Christopher A. Viehbacher - President and CEO since 2022
- Robin C. Kramer - Chief Financial Officer since 2025
- Susan H. Alexander - Chief Legal Officer since 2005
- Priya A. Singhal - Head of Development since 2023
- Nicole C. Murphy - Head of Pharmaceutical Operations and Technology since 2022
Frequently Asked Questions
Who is the CEO of Biogen?
Christopher A. Viehbacher has served as President and CEO of Biogen since November 2022.
What type of organizational structure does Biogen use?
Biogen uses a hybrid enterprise structure with major functions reporting directly to the CEO.
How many direct reports does Biogen's CEO have?
Biogen’s CEO has five direct executive reports.
How has Biogen's leadership changed recently?
Recent changes include the promotion of Robin Kramer to CFO in 2025 and the announced departure of Chief Legal Officer Susan Alexander in 2026.
Does Biogen have a COO?
No, Biogen does not currently have a Chief Operating Officer; operations report directly to the CEO.
Sources
- DEF 14A, Apr 28 2026
- 8-K Filing, Mar 11 2026
- SEC EDGAR: Biogen Inc. DEF 14A Proxy Statement
- SEC EDGAR: Biogen Inc. 10-K Annual Report
Reference
Cite this page
If you reference this page in research, analysis, or news writing, use one of the formats below. Citation includes the SEC filing source where applicable.
APA 7th
Creately. (2026). Biogen Inc. organizational structure. Creately. Retrieved , from https://creately.com/org-chart/fortune-500/biogen/MLA 9th
"Biogen Inc. Organizational Structure." Creately, April 1, 2026, https://creately.com/org-chart/fortune-500/biogen/. Accessed .Chicago 17
Creately. "Biogen Inc. Organizational Structure." Last modified April 1, 2026. https://creately.com/org-chart/fortune-500/biogen/.Original SEC source View on SEC ↗
Biogen Inc.. DEF 14A. Filed 2026-04-28. U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/875045/000119312526187303/d788083ddef14a.htmPermanent URL: https://creately.com/org-chart/fortune-500/biogen/ · last updated 2026-04-01